2018
DOI: 10.1139/bcb-2018-0023
|View full text |Cite
|
Sign up to set email alerts
|

Sortilin: a new player in dementia and Alzheimer-type neuropathology

Abstract: Age-related dementias are now a major mortality factor among most human populations in the world, with Alzheimer's disease (AD) being the leading dementia-causing neurodegenerative disease. The pathogenic mechanism underlying dementia disorders, and AD in particular, remained largely unknown. Efforts to develop drugs targeting the disease's hallmark lesions, such as amyloid plaque and tangle pathologies, have been unsuccessful so far. The vacuolar protein sorting 10p (Vps10p) family plays a critical role in me… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
14
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 15 publications
(18 citation statements)
references
References 65 publications
3
14
0
Order By: Relevance
“…Amyloid-beta A4 protein (APP), which is a major component of the amyloid plaques in the brain of Alzheimer’s patients [73], is 1.43× down-regulated. Extracellular SORT1, which has been reported to be involved in plaque formation [74], is 5.13× down-regulated in our study. PTGDS was 3.67× up-regulated due to GR plus RF.…”
Section: Discussionsupporting
confidence: 51%
“…Amyloid-beta A4 protein (APP), which is a major component of the amyloid plaques in the brain of Alzheimer’s patients [73], is 1.43× down-regulated. Extracellular SORT1, which has been reported to be involved in plaque formation [74], is 5.13× down-regulated in our study. PTGDS was 3.67× up-regulated due to GR plus RF.…”
Section: Discussionsupporting
confidence: 51%
“…In fact, sortilin has a fairly high affinity (Kd = 0.1–0.3 nM) to NT, comparable to that of NTR1 (Alexander and Leeman, 1998), and thus could be sensitively affected by NTR3 agonization or antagonization. More recent studies show sortilin involvement in many neurobiological and neuropathological events, such as regulation of neuronal/synaptic viability and activity via its binding and trafficking of neurotrophic factors, mood disorders, dementia and AD-type neuropathology (Hu et al, 2010; Nykjaer and Willnow, 2012; Capsoni et al, 2013; Johnson et al, 2017; Ruan et al, 2018; Xu et al, 2018). This has also raised discussion of pharmacological manipulation of sortilin as a disease modifying strategy, regardless whether it involves neurotensin signaling.…”
Section: Discussionmentioning
confidence: 99%
“…Sortilin was originally purified via receptor-associated affinity chromatography from human brain extracts and characterized as a type I transmembrane protein belonging to the vacuolar protein sorting 10 protein (VPS10P) domain receptor family (Petersen et al, 1997). Many signaling proteins have been identified as sortilin ligands in the central and peripheral systems (Mazella et al, 1998; Nykjaer and Willnow, 2012; Quistgaard et al, 2014; Xu et al, 2018). Thus, sortilin serves as an ApoE receptor on neuronal and non-neuronal cells, which may involve in the development of some cardiovascular, metabolic and neurological diseases (Carlo et al, 2013; Coutinho et al, 2013; Kjolby et al, 2015; Strong, 2018).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Recently, we reported extracellular deposition of sortilinderived C-terminal fragments in aged and AD human cerebrum (Hu et al, 2017;Xu et al, 2018). Given that they can form microscopically prominent extracellular proteopathy, we here name these sortilin fragments as "sorfra(s)."…”
Section: Introductionmentioning
confidence: 99%